Cefepim

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

β-Lactamase-resistant broad spectrum cephalosporin of the 4th generation. Cefepim is the most stable cephalosporin compared to β-lactamases.

Half-lifeThis section has been translated automatically.

2 h

Spectrum of actionThis section has been translated automatically.

Acinetobacter spp., Citrobacter spp., Enterobacter spp., E. coli, Hafnia alvei, Haemophilus spp., Klebsiella spp., Moraxella catarrhalis, Morganella morganii, Neisseria spp, Proteus spp., Providencia spp., Pseudomonas spp., Salmonella spp., Serratia spp., Shigella spp., Staphylococcus spp., Streptococcus spp.

IndicationThis section has been translated automatically.

Severe, life-threatening respiratory and bile duct infections.

Dosage and method of useThis section has been translated automatically.

2 times/day 2 g slowly i.v. or as a short infusion, in immunocompromised patients 3 times 2 g/day. Treatment duration: 7-10 days, max. 14 days.

Undesirable effectsThis section has been translated automatically.

Neurotoxicity (Payne LE et al. 2017)

PreparationsThis section has been translated automatically.

Maxipime®

LiteratureThis section has been translated automatically.

  1. Payne LE et al (2017) Cefepime-induced neurotoxicity: a systematic review. Crit Care 21:276.
  2. Lacroix C et al (2019) Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database.J Neurol Sci 398:196-201.
  3. Mullins BP et al (2018) Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study. Ann Pharmacother 52:639-644.

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer